Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products ...
GlobalData on MSN7d
FDA breakthrough status for Bluejay’s CHD therapy brelovitugThe US FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug, to treat chronic hepatitis delta ...
Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ('Ensysce' or the 'Company'), ...
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...
AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU has been approved in the US for the treatment of adult patients with unresectable or metastatic ...
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
In 2024, PF614-MPAR received Breakthrough Therapy designation from the U.S ... We will continue to quickly execute the final stages of this study using the Translational Pharmaceutics® platform ...
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
New approval brings the medicine to an earlier treatment setting and a broader patient population.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback